Aura Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Twelve Months EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(76,408) | $(58,763) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,295 | 1,177 |
| Accretion on marketable securities | (3,992) | (527) |
| Stock-based compensation expense | 8,772 | 6,412 |
| (Loss) gain on disposal of property and equipment | 208 | (22) |
| Non-cash lease expense | 1,837 | 968 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 3,579 | (3,253) |
| Other long-term assets | (86) | (423) |
| Accounts payable | (1,040) | 340 |
| Accrued expenses and other liabilities | 3,310 | 234 |
| Operating lease liabilities | (1,322) | (744) |
| Net cash used in operating activities | (63,847) | (54,601) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (709) | (1,094) |
| Purchase of marketable securities | (233,651) | (119,784) |
| Maturities of marketable securities | 120,397 | 53,009 |
| Net cash used in investing activities | (113,963) | (67,869) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 1,376 | 430 |
| Proceeds from issuance of common stock under ATM facility, net of issuance costs | 3,170 | 8,549 |
| Proceeds from follow-on issuance of common stock | 92,616 | 86,650 |
| Proceeds from ESPP purchase | 128 | — |
| Net cash provided by financing activities | 97,290 | 95,629 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (80,520) | (26,841) |
| Cash, cash equivalents and restricted cash at beginning of period | 122,370 | 149,211 |
| Cash, cash equivalents and restricted cash at end of period | $41,850 | $122,370 |
| Supplemental disclosure of cash flow information: | ||
| Purchases of property and equipment in accounts payable and accrued expenses and other liabilities | $94 | $180 |
| Initial measurement of right-of-use assets and lease liabilities | $20 | — |
| Right-of-use assets obtained in exchange for operating lease liabilities | — | $21,210 |
| Loss on termination of operating lease | — | $296 |
| Disposal of equipment | $1,333 | — |
| The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statements of cash flows (in thousands): | ||
| December 31, | ||
| 2023 | 2022 | |
| Cash and cash equivalents, end of period | $41,063 | $121,582 |
| Short-term restricted cash, end of period | 19 | 20 |
| Long-term restricted cash, end of period | 768 | 768 |
| Cash, cash equivalents and restricted cash at end of period | $41,850 | $122,370 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.